Dual VEGF/VEGFR inhibition in advanced solid malignancies

References

• Epstein RJ. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev 2007; 26:443 - 52; http://dx.doi.org/10.1007/s10555-007-9071-1; PMID: 17786538
   PubMed Web of Science ®Google Scholar
• Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133:275 - 88; http://dx.doi.org/10.1084/jem.133.2.275; PMID: 4332371
   PubMed Web of Science ®Google Scholar
• Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175:409 - 16; http://dx.doi.org/10.1097/00000658-197203000-00014; PMID: 5077799
   PubMed Web of Science ®Google Scholar
• Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219:983 - 5; http://dx.doi.org/10.1126/science.6823562; PMID: 6823562
   PubMed Web of Science ®Google Scholar
• Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, Manseau EJ, Dvorak HF. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996; 56:172 - 81; PMID: 8548760
   PubMed Web of Science ®Google Scholar
• Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246:1309 - 12; http://dx.doi.org/10.1126/science.2479987; PMID: 2479987
   PubMed Web of Science ®Google Scholar
• Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306 - 9; http://dx.doi.org/10.1126/science.2479986; PMID: 2479986
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427 - 34; http://dx.doi.org/10.1056/NEJMoa021491; PMID: 12890841
   PubMed Web of Science ®Google Scholar
• Rini BI. Sunitinib. Expert Opin Pharmacother 2007; 8:2359 - 69; http://dx.doi.org/10.1517/14656566.8.14.2359; PMID: 17927489
   PubMed Web of Science ®Google Scholar
• Moreno Garcia V, Basu B, Molife LR, Kaye SB. Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res 2012; 18:3750 - 61; http://dx.doi.org/10.1158/1078-0432.CCR-11-1275; PMID: 22547772
   PubMed Web of Science ®Google Scholar
• Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, et al. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009; 15:6277 - 83; http://dx.doi.org/10.1158/1078-0432.CCR-09-0717; PMID: 19773375
   PubMed Web of Science ®Google Scholar
• Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer P, Ronnen E, Ishill N, Patil S, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:1432 - 9; http://dx.doi.org/10.1200/JCO.2008.19.0108; PMID: 19224847
   PubMed Web of Science ®Google Scholar
• Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S, Suva LJ, Gruenwald JM, Kern S, Zhan F, et al. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica 2011; 96:333 - 6; http://dx.doi.org/10.3324/haematol.2010.031302; PMID: 20952514
   PubMed Web of Science ®Google Scholar
• Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Ivy P, Chen HX, Dowlati A, et al. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol 2010; 28:e284 - 5, author reply e286-7; http://dx.doi.org/10.1200/JCO.2009.27.1759; PMID: 20439632
   PubMedGoogle Scholar
• Vlaykova T, Laurila P, Muhonen T, Hahka-Kemppinen M, Jekunen A, Alitalo K, Pyrhönen S. Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. Melanoma Res 1999; 9:59 - 68; http://dx.doi.org/10.1097/00008390-199902000-00008; PMID: 10338335
   PubMed Web of Science ®Google Scholar
• Döme B, Paku S, Somlai B, Tímár J. Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. J Pathol 2002; 197:355 - 62; http://dx.doi.org/10.1002/path.1124; PMID: 12115882
   PubMed Web of Science ®Google Scholar
• Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR 3rd. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol 2002; 20:1826 - 31; http://dx.doi.org/10.1200/JCO.2002.07.082; PMID: 11919240
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368 - 80; http://dx.doi.org/10.1200/JCO.2002.10.088; PMID: 12409337
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis. Annu Rev Med 2006; 57:1 - 18; http://dx.doi.org/10.1146/annurev.med.57.121304.131306; PMID: 16409133
   PubMed Web of Science ®Google Scholar
• Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002; 29:Suppl 16 3 - 9; http://dx.doi.org/10.1053/sonc.2002.37265; PMID: 12516032
   PubMed Web of Science ®Google Scholar
• Postovit LM, Seftor EA, Seftor RE, Hendrix MJ. Influence of the microenvironment on melanoma cell fate determination and phenotype. Cancer Res 2006; 66:7833 - 6; http://dx.doi.org/10.1158/0008-5472.CAN-06-0731; PMID: 16912153
   PubMed Web of Science ®Google Scholar
• Pötgens AJ, Lubsen NH, van Altena MC, Schoenmakers JG, Ruiter DJ, de Waal RM. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 1995; 146:197 - 209; PMID: 7531947
   PubMed Web of Science ®Google Scholar
• Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int 2006; 70:16 - 23; http://dx.doi.org/10.1038/sj.ki.5001535; PMID: 16760911
   PubMed Web of Science ®Google Scholar
• Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008; 3:249 - 77; http://dx.doi.org/10.1146/annurev.pathmechdis.3.121806.154311; PMID: 18215115
   PubMed Web of Science ®Google Scholar
• Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129 - 36; http://dx.doi.org/10.1056/NEJMoa0707330; PMID: 18337603
   PubMed Web of Science ®Google Scholar
• Zaki KA, Basu B, Corrie P. The role of angiogenesis inhibitors in the management of melanoma. Curr Top Med Chem 2012; 12:32 - 49; http://dx.doi.org/10.2174/156802612798919240; PMID: 22196268
   PubMed Web of Science ®Google Scholar
• Griffioen AW, Mans LA, de Graaf AM, Nowak-Sliwinska P, de Hoog CL, de Jong TA, Vyth-Dreese FA, van Beijnum JR, Bex A, Jonasch E. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 2012; 18:3961 - 71; http://dx.doi.org/10.1158/1078-0432.CCR-12-0002; PMID: 22573349
   PubMed Web of Science ®Google Scholar
• Cascone T, Heymach JV. Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?. J Clin Oncol 2012; 30:441 - 4; http://dx.doi.org/10.1200/JCO.2011.38.7621; PMID: 22184396
   PubMed Web of Science ®Google Scholar
• Basu B, Biswas S, Wrigley J, Sirohi B, Corrie P. Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. Expert Rev Anticancer Ther 2009; 9:1583 - 98; http://dx.doi.org/10.1586/era.09.135; PMID: 19895243
   PubMed Web of Science ®Google Scholar
• Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005; 9:267 - 85; http://dx.doi.org/10.1111/j.1582-4934.2005.tb00355.x; PMID: 15963249
   PubMed Web of Science ®Google Scholar
• Monnier J, Samson M. Prokineticins in angiogenesis and cancer. Cancer Lett 2010; 296:144 - 9; http://dx.doi.org/10.1016/j.canlet.2010.06.011; PMID: 20633984
   PubMed Web of Science ®Google Scholar
• Shojaei F, Wu X, Zhong C, Yu L, Liang X-H, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007; 450:825 - 31; http://dx.doi.org/10.1038/nature06348; PMID: 18064003
   PubMed Web of Science ®Google Scholar
• Brennecke S, Deichmann M, Naeher H, Kurzen H. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res 2005; 15:515 - 22; http://dx.doi.org/10.1097/00008390-200512000-00006; PMID: 16314737
   PubMed Web of Science ®Google Scholar
• Chua R, Setzer S, Govindarajan B, Sexton D, Cohen C, Arbiser JL. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. J Am Acad Dermatol 2009; 60:758 - 66; http://dx.doi.org/10.1016/j.jaad.2009.01.018; PMID: 19389518
   PubMed Web of Science ®Google Scholar
• Dréau D, Foster M, Hogg M, Swiggett J, Holder WD, White RL. Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma. Oncol Res 2000; 12:241 - 51; PMID: 11417749
   PubMed Web of Science ®Google Scholar
• Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 2007; 13:2422 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-06-1805; PMID: 17438101
   PubMed Web of Science ®Google Scholar
• Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, Augustin HG. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 2009; 15:1384 - 92; http://dx.doi.org/10.1158/1078-0432.CCR-08-1615; PMID: 19228739
   PubMed Web of Science ®Google Scholar
• Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kähäri VM, Pyrhönen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 2005; 11:5158 - 66; http://dx.doi.org/10.1158/1078-0432.CCR-04-2478; PMID: 16033831
   PubMed Web of Science ®Google Scholar
• Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med Oncol 2008; 25:431 - 6; http://dx.doi.org/10.1007/s12032-008-9058-y; PMID: 18363112
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Leonardi E, Ottaiano A, Napolitano M, Scala S, Castello G. Prognostic value of serum VEGF in melanoma patients: a pilot study. Anticancer Res 2004; 24:4255 - 8; PMID: 15736481
   PubMed Web of Science ®Google Scholar
• Osella-Abate S, Quaglino P, Savoia P, Leporati C, Comessatti A, Bernengo MG. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res 2002; 12:325 - 34; http://dx.doi.org/10.1097/00008390-200208000-00004; PMID: 12170181
   PubMed Web of Science ®Google Scholar
• Straume O, Akslen LA. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol 2002; 160:1009 - 19; http://dx.doi.org/10.1016/S0002-9440(10)64922-X; PMID: 11891198
   PubMed Web of Science ®Google Scholar
• Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19:577 - 83; PMID: 11208853
   PubMed Web of Science ®Google Scholar
• Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, Meng YG, Ferrara N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A 2009; 106:6742 - 7; http://dx.doi.org/10.1073/pnas.0902280106; PMID: 19346489
   PubMed Web of Science ®Google Scholar
• Shojaei F, Ferrara N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res 2008; 68:5501 - 4; http://dx.doi.org/10.1158/0008-5472.CAN-08-0925; PMID: 18632597
   PubMed Web of Science ®Google Scholar
• Shojaei F, Singh M, Thompson JD, Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A 2008; 105:2640 - 5; http://dx.doi.org/10.1073/pnas.0712185105; PMID: 18268320
   PubMed Web of Science ®Google Scholar
• Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007; 450:825 - 31; http://dx.doi.org/10.1038/nature06348; PMID: 18064003
   PubMed Web of Science ®Google Scholar
• Gardizi M, Kurschat C, Riese A, Hahn M, Krieg T, Mauch C, Kurschat P. A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma. Arch Dermatol Res 2012; 304:397 - 400; http://dx.doi.org/10.1007/s00403-012-1228-2; PMID: 22410864
   PubMed Web of Science ®Google Scholar
• Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippitt CH Jr., Brown JV 3rd, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012; 30:362 - 71; http://dx.doi.org/10.1200/JCO.2010.34.3178; PMID: 22184370
   PubMed Web of Science ®Google Scholar
• Rosen LSMD, Cohen RB, Gordon MS, Goldman JW, Bear IK, Byrnes B, Perea R, Schoenfeld SL, Gollerkeri A. First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. J Clin Oncol 2010; 28:Suppl abstr 2524
   Web of Science ®Google Scholar
• Ugarte-Berzal E, Redondo-Muñoz J, Eroles P, Del Cerro MH, García-Marco JA, Terol MJ, García-Pardo A. VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration. Blood 2010; 115:846 - 9; http://dx.doi.org/10.1182/blood-2009-08-239426; PMID: 19965686
   PubMed Web of Science ®Google Scholar
• Zhang H, Vakil V, Braunstein M, Smith ELP, Maroney J, Chen L, Dai K, Berenson JR, Hussain MM, Klueppelberg U, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005; 105:3286 - 94; http://dx.doi.org/10.1182/blood-2004-06-2101; PMID: 15618473
   PubMed Web of Science ®Google Scholar
• Beerepoot LV, Mehra N, Vermaat JSP, Zonnenberg BA, Gebbink MFGB, Voest EE. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004; 15:139 - 45; http://dx.doi.org/10.1093/annonc/mdh017; PMID: 14679134
   PubMed Web of Science ®Google Scholar
• Beerepoot LV, Mehra N, Linschoten F, Jorna AS, Lisman T, Verheul HMW, Voest EE. Circulating endothelial cells in cancer patients do not express tissue factor. Cancer Lett 2004; 213:241 - 8; http://dx.doi.org/10.1016/j.canlet.2004.04.019; PMID: 15327840
   PubMed Web of Science ®Google Scholar
• Kim HK, Song KS, Kim HO, Chung J-H, Lee KR, Lee Y-J, Lee DH, Lee ES, Kim HK, Ryu KW, et al. Circulating numbers of endothelial progenitor cells in patients with gastric and breast cancer. Cancer Lett 2003; 198:83 - 8; http://dx.doi.org/10.1016/S0304-3835(03)00268-4; PMID: 12893434
   PubMed Web of Science ®Google Scholar
• Gruenwald V, Beutel G, Schuch-Jantsch S, Reuter C, Ivanyi P, Ganser A, Haubitz M. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer 2010; 10:695; http://dx.doi.org/10.1186/1471-2407-10-695; PMID: 21194438
   PubMed Web of Science ®Google Scholar
• Triozzi PL, Achberger S, Aldrich W, Singh AD, Grane R, Borden EC. The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon. J Transl Med 2012; 10:241; http://dx.doi.org/10.1186/1479-5876-10-241; PMID: 23217102
   PubMed Web of Science ®Google Scholar
• Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q, Fan K, Yan H, Lu D, Ye Z, Hao J, et al. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 2012; 120:2330 - 9; http://dx.doi.org/10.1182/blood-2012-01-406108; PMID: 22718841
   PubMed Web of Science ®Google Scholar
• Woywodt A, Blann AD, Kirsch T, Erdbruegger U, Banzet N, Haubitz M, Dignat-George F. Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J Thromb Haemost 2006; 4:671 - 7; http://dx.doi.org/10.1111/j.1538-7836.2006.01794.x; PMID: 16460450
   PubMed Web of Science ®Google Scholar